$XENE News

Xenon Pharmaceuticals To Present 6 Azetukalner Data Sets, Including Encore Oral Presentation Of Topline Phase 3 X-TOLE2 Results At European Epilepsy Congress, Taking Place September 5-9, 2026

Xenon Pharmaceuticals (NASDAQ:XENE) Presents High-Quality Technical Breakout Setup

Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $81

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript

Xenon Pharmaceuticals Q2 EPS $(1.11) Beats $(1.15) Estimate

Xenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial Execution

Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why

Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82

JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)

What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing

Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $80

A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway

Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $82

Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript